Globe News Wire
02 Nov 2025, 22:10 UTC · 45w ago
Verdict
Headline takes no side. We score ALVO −0.70 — strongly bearish.
−0.70strongly bearish
More negative than 85% of ticker scores this week
Which stocks this story touches
More negative than 85% of ticker scores this week
The FDA delayed the marketing authorization for AVT05 due to manufacturing facility issues, leading the company to lower its 2025 revenue and EBITDA forecasts.
More negative than 71% of ticker scores this week
As a US marketing partner for Alvotech, the delay in the approval of the Simponi biosimilar represents a loss of a potential near-term product launch.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a partner in a general list of collaborators with no specific impact on its current operations.
More positive than 77% of relationship scores this week
[mutual] Kamada Ltd. is a partner of Alvotech for sales, marketing, and distribution in Israel.
More positive than 77% of relationship scores this week
[mutual] Teva Pharmaceuticals is a marketing partner for Alvotech in the United States.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Schwab Network
1h ago
−31.0%
Price agrees with the score
$5.28 vs $7.65 close before publication (Oct 31) · not market-adjusted
ALVO chart →
